Genus Capital Management’s Boston Scientific BSX Stock Holding History

Genus Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,325	Closed	-$317K	–	202
2025 Q4	$317K	Sell	3,325 -25,722	-89%	-$2.52M	0.04%	167
2025 Q3	$2.84M	Sell	29,047 -22,365	-44%	-$2.32M	0.33%	96
2025 Q2	$5.52M	Sell	51,412 -32,478	-39%	-$3.29M	0.7%	45
2025 Q1	$8.46M	Buy	+83,890	New	+$8.45M	1.23%	23

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Genus Capital Management's BSX Position: Q1 2026 in Review

Genus Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 3,325 shares — an estimated $317K sold.

Genus Capital Management first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $8.46M in Q1 2025. 1,676 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Genus Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Genus Capital Management sold 3,325 Boston Scientific shares in Q1 2026, an estimated $317K.
Genus Capital Management first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
Genus Capital Management's Boston Scientific position peaked at $8.46M in Q1 2025.
1,676 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Genus Capital Management's 13F filing for Q1 2026, filed 4 May 2026.